Mainz Biomed Analyst Ratings
Mainz Biomed Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
09/14/2023 | 112.26% | Cantor Fitzgerald | → $9 | Reiterates | Overweight → Overweight |
08/22/2023 | 112.26% | Cantor Fitzgerald | → $9 | Reiterates | Overweight → Overweight |
08/18/2023 | 65.09% | HC Wainwright & Co. | $10 → $7 | Reiterates | Buy → Buy |
06/01/2023 | 135.85% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
05/18/2023 | 183.02% | Cantor Fitzgerald | $15 → $12 | Maintains | Overweight |
04/27/2023 | 135.85% | HC Wainwright & Co. | $25 → $10 | Maintains | Buy |
03/30/2023 | 489.62% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
02/16/2023 | 489.62% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
02/10/2023 | 159.43% | JonesTrading | → $11 | Initiates Coverage On | → Buy |
10/25/2022 | 253.77% | Cantor Fitzgerald | → $15 | Initiates Coverage On | → Overweight |
06/21/2022 | 489.62% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
---|---|---|---|---|---|
09/14/2023 | 112.26% | 康托·菲茨杰拉德 | →$9 | 重申 | 超重→超重 |
2023年08月22日 | 112.26% | 康托·菲茨杰拉德 | →$9 | 重申 | 超重→超重 |
2023年08月18日 | 65.09% | HC Wainwright公司 | $10→$7 | 重申 | 购买→购买 |
06/01/2023 | 135.85% | HC Wainwright公司 | →$10 | 重申 | →购买 |
2023年05月18日 | 183.02% | 康托·菲茨杰拉德 | $15→$12 | 维护 | 超重 |
04/27/2023 | 135.85% | HC Wainwright公司 | $25→$10 | 维护 | 买 |
03/30/2023 | 489.62% | HC Wainwright公司 | →$25 | 重申 | →购买 |
02/16/2023 | 489.62% | HC Wainwright公司 | →$25 | 重申 | →购买 |
02/10/2023 | 159.43% | Jones Trading | →$11 | 开始承保 | →购买 |
2022年10月25日 | 253.77% | 康托·菲茨杰拉德 | →$15 | 开始承保 | →超重 |
2022年06月21日 | 489.62% | HC Wainwright公司 | →$25 | 开始承保 | →购买 |
What is the target price for Mainz Biomed (MYNZ)?
美因茨生物科技公司(MYNZ)的目标价是多少?
The latest price target for Mainz Biomed (NASDAQ: MYNZ) was reported by Cantor Fitzgerald on September 14, 2023. The analyst firm set a price target for $9.00 expecting MYNZ to rise to within 12 months (a possible 112.26% upside). 10 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2023年9月14日报道了美因茨生物化工(纳斯达克:MYNZ)的最新目标价。这家分析公司将目标价定为9美元,预计新西兰元将在12个月内上涨(可能上涨112.26%)。去年有10家分析公司公布了评级。
What is the most recent analyst rating for Mainz Biomed (MYNZ)?
美因茨生物科技公司(MYNZ)的最新分析师评级是多少?
The latest analyst rating for Mainz Biomed (NASDAQ: MYNZ) was provided by Cantor Fitzgerald, and Mainz Biomed reiterated their overweight rating.
美因茨·比默德(纳斯达克:MYNZ)的最新分析师评级由坎托·菲茨杰拉德提供,美因茨·比梅德重申其增持评级。
When is the next analyst rating going to be posted or updated for Mainz Biomed (MYNZ)?
美因茨生物科技公司(MYNZ)的下一次分析师评级将于何时发布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mainz Biomed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mainz Biomed was filed on September 14, 2023 so you should expect the next rating to be made available sometime around September 14, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括查阅公开财务报表,与美因茨生物美孚的高管和客户交谈,以及听取收益电话会议。大多数分析师每三个月就会这样做一次,所以你每年应该会得到每家公司每家公司的4个评级。美因茨·比默德的上一次评级是在2023年9月14日提交的,所以你应该预计下一次评级将在2024年9月14日左右的某个时候公布。
Is the Analyst Rating Mainz Biomed (MYNZ) correct?
分析师对美因茨-比默德(MYNZ)的评级正确吗?
While ratings are subjective and will change, the latest Mainz Biomed (MYNZ) rating was a reiterated with a price target of $0.00 to $9.00. The current price Mainz Biomed (MYNZ) is trading at is $4.24, which is within the analyst's predicted range.
虽然评级是主观的,并将发生变化,但美因茨生物美孚(MYNZ)的最新评级被重申,目标价在0.00美元至9.00美元之间。美因茨-比奥梅德目前的股价为4.24美元,处于分析师的预测区间内。